Steven Cohen’s CG Oncology CGON Stock Holding History

Steven Cohen’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$654K	Sell	9,200 -16,700	-64%	-$1.09M	﹤0.01%	3050
2026 Q1	$1.75M	Buy	+25,900	New	+$1.47M	﹤0.01%	2400

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steven Cohen's CGON Position: Q2 2026 in Review

Steven Cohen sold out of CG Oncology (CGON) in Q2 2026, closing a stake of 399,392 shares — an estimated $26.1M sold.

Steven Cohen first reported a position in CGON in Q1 2024 and held it in 9 quarters. The position peaked at $61.4M in Q3 2025. 226 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

Steven Cohen reported no remaining CG Oncology position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 399,392 CG Oncology shares in Q2 2026, an estimated $26.1M.
Steven Cohen first reported a position in CG Oncology in Q1 2024 and held it in 9 quarters.
Steven Cohen's CG Oncology position peaked at $61.4M in Q3 2025.
226 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.